ANDA 203330, held by P&L Pharmaceuticals. Fexofenadine Hydrochloride.
As of Nov 21, 2026, ANDA 203330 (Children's Fexofenadine Hydrochloride Allergy, Children's Fexofenadine Hydrochloride Hives), held by P&L Pharmaceuticals, was first approved by FDA on Nov 18, 2014, with 1 approved supplement and 0 published complete response letters.
Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 18, 2014 | Original application | Approved | None posted |
| Children's Fexofenadine Hydrochloride Allergy30MG/5ML · suspension;oral | Fexofenadine Hydrochloride | OTC |
| Children's Fexofenadine Hydrochloride Hives30MG/5ML · suspension;oral | Fexofenadine Hydrochloride | OTC |
| Mar 3, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 18, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters